EZZ Life Science Holdings Limited
ASX: EZZ
EZZ’s major earnings breakthrough in 2024 highly promising towards a rebound.
(Source: TradingView) 3-Month Performance Profile of EZZ compared to the S&P/ASX 200 (XJO).
EZZ Life Science has demonstrated a strong and highly promising long-term growth trajectory, with revenues increasing from $17.3 million in 2020 to $66 million in 2024. Notably, the
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
